Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Summary

The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.

Timeline

Start

2022-12-13

Primary completion

2027-10

Completion

2027-11

Drugs

Indications